NBTX

NBTX

USD

Nanobiotix S.A. American Depositary Shares

$19.330+0.560 (2.983%)

Real-time Price

Healthcare
Biotechnology
France

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$18.770

High

$20.261

Low

$18.580

Volume

0.07M

Company Fundamentals

Market Cap

1.1B

Industry

Biotechnology

Country

France

Trading Stats

Avg Volume

0.08M

Exchange

NMS

Currency

USD

52-Week Range

Low $2.76Current $19.330High $30.35

Related News

GlobeNewswire

NANOBIOTIX to Participate in Investor Conferences the Week of November 10th

PARIS and CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ:NBTX - the "Company"), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand

View more
NANOBIOTIX to Participate in Investor Conferences the Week of November 10th
GlobeNewswire

NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth

$71 million in funding would extend Nanobiotix cash visibility into early 2028Transaction enables Nanobiotix development beyond key milestones in head and neck cancer and lung cancerFinancing establishes financial

View more
NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
GlobeNewswire

NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control

PARIS and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand

View more
NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control